Analogue-based Drug Discovery
The easiest way to create a new drug is to modify an existing one. These so-called drug analogs account for about half of all new drugs and are of tremendous importance both for medical and financial reasons. In addition, drug analogs can be modeled on naturally occurring bioactive substances that do not make good drugs on their own, thereby considerably increasing the therapeutic range of pharmaceutical medicine.This first authoritative and systematic overview of past and current strategies for successful drug development by modification spans all important drug classes and all major therapeutic fields. It discusses analog-based drug discove…
Mehr
CHF 262.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
V112:
Lieferbar in ca. 10-20 Arbeitstagen
Produktdetails
Weitere Autoren: Fischer, János / Ganellin, C. Robin
- ISBN: 978-3-527-31257-3
- EAN: 9783527312573
- Produktnummer: 1687289
- Verlag: Wiley-VCH
- Sprache: Englisch
- Erscheinungsjahr: 2006
- Seitenangabe: 606 S.
- Masse: H24.0 cm x B17.0 cm x D3.3 cm 1'264 g
- Abbildungen: s/w. Tab.
- Gewicht: 1264
Über den Autor
Janos Fischer is research laboratory head at Richter Ltd. (Budapest, Hungary). He received his education in Hungary with B.Sc. and P.h. D. degrees in organic chemistry at the Eotvos University of Budapest with Professor A. Kucsman. Between 1976-78 he was a Humboldt fellow at the University of Bonn with Professor W. Steglich. He has worked at Richter Ltd. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest now is analog-based drug discovery. He is author of some 100 patents and scientific publications. In 2004 he was elected member of the Chemistry and Human Health Division of IUPAC. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co-inventors of the revolutionary drug cimetidine (also known as Tagamet). In 1986 he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Emeritus Professor of Medicinal Chemistry. Professor Ganellin is co-inventor on over 160 patents and has authored 250 scientific publications. He was President of the Medicinal Chemistry Section of IUPAC and is currently Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
4 weitere Werke von IUPAC:
Bewertungen
Anmelden